|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BUB1B |
Gene summary for BUB1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BUB1B | Gene ID | 701 |
| Gene name | BUB1 mitotic checkpoint serine/threonine kinase B | |
| Gene Alias | BUB1beta | |
| Cytomap | 15q15.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O60566 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 701 | BUB1B | ATC2 | Human | Thyroid | ATC | 1.60e-07 | 6.00e-01 | 0.34 |
| 701 | BUB1B | ATC4 | Human | Thyroid | ATC | 6.21e-03 | 1.40e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190209911 | Thyroid | ATC | regulation of metaphase/anaphase transition of cell cycle | 44/6293 | 63/18723 | 4.45e-09 | 9.97e-08 | 44 |
| GO:004478411 | Thyroid | ATC | metaphase/anaphase transition of cell cycle | 45/6293 | 65/18723 | 4.62e-09 | 1.03e-07 | 45 |
| GO:003304511 | Thyroid | ATC | regulation of sister chromatid segregation | 48/6293 | 72/18723 | 9.86e-09 | 2.05e-07 | 48 |
| GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
| GO:200125111 | Thyroid | ATC | negative regulation of chromosome organization | 54/6293 | 86/18723 | 2.84e-08 | 5.41e-07 | 54 |
| GO:005178311 | Thyroid | ATC | regulation of nuclear division | 77/6293 | 139/18723 | 1.01e-07 | 1.70e-06 | 77 |
| GO:190199115 | Thyroid | ATC | negative regulation of mitotic cell cycle phase transition | 94/6293 | 179/18723 | 1.33e-07 | 2.19e-06 | 94 |
| GO:004583911 | Thyroid | ATC | negative regulation of mitotic nuclear division | 34/6293 | 48/18723 | 1.49e-07 | 2.41e-06 | 34 |
| GO:004593015 | Thyroid | ATC | negative regulation of mitotic cell cycle | 117/6293 | 235/18723 | 1.93e-07 | 3.05e-06 | 117 |
| GO:00458414 | Thyroid | ATC | negative regulation of mitotic metaphase/anaphase transition | 29/6293 | 40/18723 | 5.62e-07 | 7.96e-06 | 29 |
| GO:00330474 | Thyroid | ATC | regulation of mitotic sister chromatid segregation | 32/6293 | 46/18723 | 6.68e-07 | 9.13e-06 | 32 |
| GO:005178411 | Thyroid | ATC | negative regulation of nuclear division | 37/6293 | 56/18723 | 6.82e-07 | 9.30e-06 | 37 |
| GO:00330464 | Thyroid | ATC | negative regulation of sister chromatid segregation | 30/6293 | 43/18723 | 1.36e-06 | 1.71e-05 | 30 |
| GO:00330484 | Thyroid | ATC | negative regulation of mitotic sister chromatid segregation | 30/6293 | 43/18723 | 1.36e-06 | 1.71e-05 | 30 |
| GO:20008164 | Thyroid | ATC | negative regulation of mitotic sister chromatid separation | 30/6293 | 43/18723 | 1.36e-06 | 1.71e-05 | 30 |
| GO:00513044 | Thyroid | ATC | chromosome separation | 55/6293 | 96/18723 | 1.58e-06 | 1.93e-05 | 55 |
| GO:000709312 | Thyroid | ATC | mitotic cell cycle checkpoint | 69/6293 | 129/18723 | 2.52e-06 | 2.96e-05 | 69 |
| GO:00070944 | Thyroid | ATC | mitotic spindle assembly checkpoint | 27/6293 | 38/18723 | 2.64e-06 | 3.06e-05 | 27 |
| GO:00711734 | Thyroid | ATC | spindle assembly checkpoint | 27/6293 | 38/18723 | 2.64e-06 | 3.06e-05 | 27 |
| GO:00711744 | Thyroid | ATC | mitotic spindle checkpoint | 27/6293 | 38/18723 | 2.64e-06 | 3.06e-05 | 27 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BUB1B | SNV | Missense_Mutation | novel | c.1378N>G | p.Gln460Glu | p.Q460E | O60566 | protein_coding | tolerated(0.25) | benign(0.392) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
| BUB1B | SNV | Missense_Mutation | novel | c.2006N>C | p.Leu669Pro | p.L669P | O60566 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
| BUB1B | SNV | Missense_Mutation | novel | c.361T>A | p.Phe121Ile | p.F121I | O60566 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
| BUB1B | SNV | Missense_Mutation | rs761128578 | c.2782A>G | p.Ser928Gly | p.S928G | O60566 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BUB1B | SNV | Missense_Mutation | novel | c.721N>G | p.Pro241Ala | p.P241A | O60566 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| BUB1B | SNV | Missense_Mutation | c.863N>T | p.Ser288Phe | p.S288F | O60566 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| BUB1B | SNV | Missense_Mutation | novel | c.209C>A | p.Thr70Asn | p.T70N | O60566 | protein_coding | deleterious(0.02) | benign(0.079) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BUB1B | SNV | Missense_Mutation | novel | c.2644N>A | p.Asp882Asn | p.D882N | O60566 | protein_coding | tolerated(0.17) | probably_damaging(0.993) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| BUB1B | SNV | Missense_Mutation | c.41C>T | p.Ala14Val | p.A14V | O60566 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AA-3869-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | PD | |
| BUB1B | SNV | Missense_Mutation | novel | c.923N>C | p.Leu308Pro | p.L308P | O60566 | protein_coding | deleterious(0.04) | probably_damaging(0.972) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |